Caffeine
- Generic Name
- Caffeine
- Brand Names
- Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10N4O2
- CAS Number
- 58-08-2
- Unique Ingredient Identifier
- 3G6A5W338E
- Background
Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, whic...
- Indication
Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broa...
- Associated Conditions
- Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
- Associated Therapies
- Analgesia, Antacid therapy, Athletic Performance
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06686628
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
- Conditions
- Interventions
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 29
- Registration Number
- NCT06636825
- Locations
- 🇺🇸
US Army Research Institute of Environmental Medicine, Natick, Massachusetts, United States
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06632990
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06564441
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 30
- Registration Number
- NCT06416956
- Locations
- 🇬🇧
Newborn Care Unit, John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom
Caffeine Use in the Management of Preterm Infants
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 40
- Registration Number
- NCT06327152
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT05932277
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT05852769
- Locations
- 🇺🇸
ICON plc, Millcreek, Utah, United States
Consequences of Caffeine Intake in Sleep Restricted Teenagers
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Psychiatric Hospital of the University of Basel
- Target Recruit Count
- 54
- Registration Number
- NCT05790161
- Locations
- 🇨🇭
Centre for Chronobiology, Basel, Switzerland
Oxygen Toxicity: Mechanisms in Humans
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Duke University
- Target Recruit Count
- 62
- Registration Number
- NCT05761756
- Locations
- 🇺🇸
Duke University Health Sustem, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.